The U.S. Food and Drug Administration has approved Roctavian, an adeno-associated virus vector-based gene therapy for the treatment of adults with severe hemophilia A.
The FDA granted approval of Roctavian to BioMarin Pharmaceutical Inc.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
by Joji Xavier
For comments and feedback: contact editorial@rttnews.com